Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Neurogastroenterol Motil. 2016 Feb 27;28(8):1157–1165. doi: 10.1111/nmo.12813

Table 1.

Baseline characteristics of study subjects.

N Mean (SD) or n (%)

Age at time of manometry, years 74 50.5 (12.4)

Sex, n (% women) 74 62 (84)

BMI, kg/m2 73 25.4 (5.9)

Race, n (% white) 74 53 (72)

SSc Disease subtype
 n (% diffuse) 23 (31)
 n (% limited) 74 34 (46)
 n (% SSS) 6 (8)
 n (% other 10 (14)

Modified Rodnan Skin Score 52 10.4 (11.4)

Duration since first Raynaud, months 67 111.4 (119.4)

Duration since first non-Raynaud, months 70 81.7 (84.9)

On PPI 74 73 (99)

Serum autoantibodies, n (% positive)
Anti-nuclear antibody (ANA) 67 65 (97)
Anti-centromere antibody (ACA) 64 13 (20)
Scl-70 65 23 (35)
RNA polymerase III 52 5 (10)

Pulmonary Function Tests, mean (SD)
FVC % predicted 46 77.2 (20.5)
DLCO % predicted 46 58.1 (20.4)

ILD, n (% present) 63 42 (67)

Symptoms, n (% positive)
Dysphagia 74 60 (81)
Reflux (heartburn or regurgitation) 74 61 (82)

Patients with esophageal motility diagnosis of absent contractility, ineffective esophageal motility, and normal esophageal motility are included. BMI – body mass index. PPI – proton pump inhibitor. FVC – forced vital capacity. DLCO – diffusing capacity for carbon monoxide. ILD – interstitial lung disease.